MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER
For a long time, chemotherapy remained the main treatment option for metastatic urothelial carcinoma (mUC). Over the past year, there have been revolutionary changes associated with the approval of five new drugs aimed at blocking the interaction between the surface protein of T-lymphocytes PD-1 and...
Saved in:
| Main Authors: | R. A. Gafanov, S. V. Garmash, I. B. Kravtsov, S. V. Fastovets |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
QUASAR, LLC
2018-03-01
|
| Series: | Исследования и практика в медицине |
| Subjects: | |
| Online Access: | https://www.rpmj.ru/rpmj/article/view/246 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review)
by: K. V. Menshikov, et al.
Published: (2022-10-01) -
PD-L1 as a Potential Target in Cancer Therapy (Review)
by: N. N. Andrusova, et al.
Published: (2021-02-01) -
Modern possibilities of using immunotherapy in the treatment of cervical cancer
by: A. V. Tarasova, et al.
Published: (2021-09-01) -
The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience
by: Fateen Ata, et al.
Published: (2024-12-01) -
NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors
by: Michael S. Chang, MD, et al.
Published: (2025-02-01)